Will Beovu Be A Slow-Burning Blockbuster?
DME Data Boosts Novartis Eye Drug
Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.
